FluoGuide strengthen its protection on FG001 with the European granting of patent
FluoGuide A/S (“FluoGuide”) is pleased to announce the grant of European patent No. EP3193945 “uPAR targeting peptide for use in peroperative optical imaging of invasive cancer”, which is the core patent protecting FG001 in Europe. The patent protection is valid until September 2034. The FG001 product patent was granted in USA (US10,111,969B2) in 2018.
FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of their cure. It can also reduce costs for the health care system to the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patient with glioblastoma as a proof-of-concept clinical study and announce the first result in summer 2020.
The product patent on FG001 is with the granting in Europe now granted on FluoGuide’s two main markets – USA and Europe. FluoGuide acquired this patent family in relation to the IPO in 2019 and FluoGuide now owns this patent family.
Morten Albrechtsen, CEO comments:
“We are happy to announce that FluoGuide has now been awarded this important product patent on FG001 in Europe. It is an exciting start of 2020 being an important year for FluoGuide”
FluoGuide A/S is obliged to publish this information in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on 7 January 2020.
For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
__________________________________________________________________________________
About FluoGuide
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.
About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.
Tags: